טוען...
Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
BACKGROUND: In the current study, we aimed to investigate the efficacy and safety of intravenous immunoglobulin (IVIg)-SN 10%, a new 10% IVIg formulation, in adult patients with severe primary immune thrombocytopenia (ITP; platelet count < 20 × 10(9)/L). METHODS: Patients diagnosed as primary ITP...
שמור ב:
| הוצא לאור ב: | J Korean Med Sci |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Academy of Medical Sciences
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5934518/ https://ncbi.nlm.nih.gov/pubmed/29736158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2018.33.e142 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|